Home / News / Ex-pharma Vice President appointed to key national health role

Ex-pharma Vice President appointed to key national health role

A former Vice President of AstraZeneca has been appointed to a key national health role – less than a year after joining the NHS.

Professor Mike Hannay is to take up the position of Vice Chair of the national AHSN Network, a collaboration of England’s 15 Academic Health Science Networks (AHSNs).

Mike’s new role will operate alongside his current position as Managing Director of the East Midlands AHSN, a post he took up in July 2016.

AHSNs were established by the NHS in 2013 with a remit to work across health, social care, academia and industry to speed up the adoption and spread of innovation. Since 2013 more than 200 innovations have been introduced through AHSN influence benefiting over 6 million patients and leveraging £330 million investment.

The NHS recently announced that AHSNs will be relicensed for a further period from April 2018, and will continue to operate as a key innovation delivery arm for the NHS.

As Vice Chair of the AHSN Network, Mike will play a central role in supporting the AHSNs through the current relicensing process, and an important focus will be to continue to develop national collaboration between health and industry bodies.

Mike has over 25 years’ national and international experience within the pharmaceutical industry, with a track record of building collaboration with healthcare and academia. Previous roles include ThermoFisher Scientific (Vice President for the UK BioPharma Services Division) and AstraZeneca (Vice President of Medicines Development).

“I’m honoured to take up the position of vice-chair of the AHSN Network,” said Mike. “Our next licence present new and exciting opportunities to expand our national collaboration with industry as we collectively deliver NHS programmes and contribute to the adoption of spread of products and services developed by commercial innovators.”

Mike added: “The NHS is facing enormous challenges and Academic Health Science Networks have important roles to play in supporting our health and industry partners to transform services for patients throughout England. During our first licence we have delivered improved clinical outcomes and better patient experiences, reducing the cost of care and stimulating wealth creation.

“This is clearly evidenced by our track record; over the past 4 years our work with industry and health innovators has driven the adoption of hundreds of products and services, leveraging over £330M investment and helping create more than 500 jobs.”

Chair of the AHSN Network, Dr Liz Mear, said Mike’s industry experience will be hugely valuable: “We are at a key point in our relicensing journey and Mike’s extensive industry experience – and reputation for developing positive partnerships between the health and commercial sectors – will help us plan to take on board fresh challenges, such as the Accelerated Access Review and development of the next wave of test beds.”

Mike lives in Derby and is married with two grown-up children.

To find out more about the East Midlands Academic Health Science Network, please click here.

Check Also

£500k Funding Boost for Regenerative Medicine Firm

A regenerative medicine company which has developed a therapy that can help prevent sight loss …